QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer

Friday, January 19, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

Extended labeling claim adds detection of three additional gene mutations to provide the most comprehensive mutation panel for GILOTRIF®

GERMANTOWN, Maryland and HILDEN, Germany, January 18, 2018 /PRNewswire/ --

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN's therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim's targeted therapy GILOTRIF® (afatinib) for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-resistant epidermal growth factor receptor (EGFR) mutations. The approval extends the labeling claim to include detection of EGFR mutations L681Q, G719X and S768I to aid the identification of NSCLC patients for whom GILOTRIF® (afatinib) is indicated. The therascreen® EGFR RGQ PCR Kit now detects the most comprehensive panel of EGFR mutations in which the safety and efficacy of GILOTRIF® (afatinib) have been established.

Click here for the full press release.

https://corporate.qiagen.com/newsroom/press-releases/2017/20180118_therascreen_EGFR?sc_lang=en

Contacts: 

QIAGEN 

Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711

Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com  +49-2103-29-11826

SOURCE QIAGEN N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store